4-(5-iodopyrimidin-2-yl)morpholine | 866534-08-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(5-iodopyrimidin-2-yl)morpholine
• CAS: 866534-08-9
• 化学式: C₈H₁₀IN₃O
• 分子量: 291.091
• InChiKey: IXQHAQNJMZJCLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(5-iodopyrimidin-2-yl)morpholine 在 正丁基锂 、 重水 作用下， 以 四氢呋喃 为溶剂， 以130 mg的产率得到4-(pyrimidin-2-yl-5-d)morpholine
  参考文献：
  名称：

  Substrate-controlled divergent remote C–H and N–H polyfluoroarylation of 2-aminopyrimidines with polyfluoroarenes via Pd(ii)/Pd(0) catalysis

  摘要：

  Substrate-controlled product divergence is demonstrated in Pd-catalyzed reaction of 2-aminopyrimidines. Remote C5–H polyfluoroarylation occurs with N-alkylpyrimidine-2-amines, while N–H polyfluoroarylation is dominant for N-aryl-pyrimidine-2-amines.

  DOI：

  10.1039/d4cc01518e
• 作为产物：
  描述：

  4-(嘧啶-2-基)吗啉 在 N-碘代丁二酰亚胺 、 三氟乙酸 作用下， 生成 4-(5-iodopyrimidin-2-yl)morpholine
  参考文献：
  名称：

  Substrate-controlled divergent remote C–H and N–H polyfluoroarylation of 2-aminopyrimidines with polyfluoroarenes via Pd(ii)/Pd(0) catalysis

  摘要：

  Substrate-controlled product divergence is demonstrated in Pd-catalyzed reaction of 2-aminopyrimidines. Remote C5–H polyfluoroarylation occurs with N-alkylpyrimidine-2-amines, while N–H polyfluoroarylation is dominant for N-aryl-pyrimidine-2-amines.

  DOI：

  10.1039/d4cc01518e

文献信息

• [EN] TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLONE UTILISÉS COMME INHIBITEURS DE LA MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2013186692A1

  公开（公告）日：2013-12-19

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式(I)的化合物及其药用盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗来自各种疾病或病况的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿关节炎、急性或慢性疼痛和神经退行性疾病。
• Tetrahydronaphthyridine derivatives and a process for preparing the same
  申请人：Kubota Hitoshi

  公开号：US20070032485A1

  公开（公告）日：2007-02-08

  A novel compound of the formula (I): wherein R 1 is alkoxycarbonyl or the like, R 2 is alkyl or the like; R 3 is hydrogen or the like; R 4 is alkylene or the like; R 5 is optionally substituted heterocyclic group; R 6 , R 7 , and R 8 are independently hydrogen; alky, alkoxy, or the like; R 10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).

  一种化合物的公式（I）：其中R1为烷氧羰基或类似物，R2为烷基或类似物；R3为氢或类似物；R4为烷基或类似物；R5为可选取代的杂环基；R6、R7和R8分别为氢、烷基、烷氧基或类似物；R10为可选取代的芳香环或类似物；或其药学上可接受的盐，该化合物具有对胆固醇酯转移蛋白（CETP）的抑制活性。
• Triazolone compounds as mPGES-1 inhibitors
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：US09096545B2

  公开（公告）日：2015-08-04

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式（I）化合物及其药学上可接受的盐，用作mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或状况引起的疼痛和/或炎症，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：US20150087646A1

  公开（公告）日：2015-03-26

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式(I)的化合物及其药学上可接受的盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1 (mPGES-1)酶的抑制剂，因此可用于治疗各种疾病或病况引起的疼痛和/或炎症，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• Triazolone compounds as MPGES-1 inhibitors
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：US10391083B2

  公开（公告）日：2019-08-27

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及作为 mPGES-1 抑制剂的式 (I) 化合物及其药学上可接受的盐。这些化合物是微粒体前列腺素 E 合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或病症引起的疼痛和/或炎症，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。